2nd Lipid Nanoparticle Development Europe Summit

With lipid nanoparticles moving beyond mRNA vaccines, biopharma are racing against the clock to exploit clinical utility to deliver more complex payloads, while optimising scalability and product quality.

Following industry progress of BioNTech entering LNP cancer vaccine trials, Moderna entering $76m collaboration with Gen Bio, and Bayer-Acuitas Therapeutics partnership using LNP for gene therapy, the field shows no signs of slowing down.

In collaboration with CPI, Pfizer, GSK, this 3-day summit will reunite 100+ senior leaders, sharing exclusive data to help you maximise this non-viral delivery system's potential. The 2nd Lipid Nanoparticle Development Europe Summit is committed to equipping you with actionable takeaways across end-to-end characterisation, biodistribution, formulation and scale up to supercharge your LNP pipeline development with therapeutic promise to patients.

Unite in October to get ahead of the curve and exploit LNP as the hottest delivery vehicle.

Visit the website for full details, early bird and group discount information.

URLs:
Website: https://go.evvnt.com/1842219-0?pid=10018
Tickets: https://go.evvnt.com/1842219-2?pid=10018
Brochure: https://go.evvnt.com/1842219-3?pid=10018
LinkedIn: https://go.evvnt.com/1842219-4?pid=10018

Prices:
Conference + 3 Workshops - Drug Developer Pricing: EUR 4546.00,
Conference + 3 Workshops - Academic Pricing: EUR 3896.00,
Conference + 3 Workshops - Service Provider Pricing: EUR 5546.00,
Conference + 2 Workshops - Drug Developer Pricing: EUR 3997.00,
Conference + 2 Workshops - Academic Pricing: EUR 3397.00,
Conference + 2 Workshops - Service Provider Pricing: EUR 4987.00,
Conference Only - Drug Developer Pricing: EUR 2899.00,
Conference Only - Academic Pricing: EUR 2399.00,
Conference Only - Service Provider Pricing: EUR 3599.00

Speakers: Phil Rye, Chief Scientific Officer, AlgiPharma AS, Alexander Kapustin, Associate Principal Scientist, AstraZeneca, Nikolaos Daskalakis, Senior Scientist, Advanced Drug Delivery, AstraZeneca, David Diaz-Oviedo, Postdoctoral Research Scientist, Bayer Pharmaceuticals, Juliana Haggerty, Head of Centre of Excellence Lipid Nanoparticles, CPI, Emily Port, Team Leader and Principal Scientist Nanopharmaceuticals, CPI, Laurent Strodiot, Director R and D, GSK, Senior Representative, Helix Biotech, Senior Representative, InProcess-LSP, Xiang Luo, Scientist, King's College London, Alexander Kros, Professor, Leiden University, Yogev Debbi, Co-Founder and CEO, Mana.bio, Dai Hayward, CEO, Micropore Technologies, Ben Knappett, Head of Science and Applications, Particle Works, Giel De Winter, Senior Technical Design Lead Innovation, Pfizer, Senior Representative, Precision Nanosystems, Dimitrios Lamprou, Professor, Queen's University Belfast, Senior Representative, ReciBio Pharm, Stephen Lock, Senior Market Development Manager, SCIEX, Lu Tian, Senior Director, LNP Platform Lead and CMC Project Management, STA Pharmaceutical, Mostafa Nakach, Global Head of Process Engineering for Biologics Drug Product Development, Sanofi, Selma Pereira Lopes, Head of Drug Product Science, The Janssen Pharmaceutical Companies of Johnson and Johnson, Federica Sebastiani, Assistant Professor, University of Copenhagen, Camilla Foged, Professor of Vaccine Design and Delivery, University of Copenhagen, Heinrich Haas, Professor, University of Mainz